Aptose Biosciences Inc. closes C$8M public offering

On November 25, 2024, Aptose Biosciences Inc. ("Aptose") closed its public offering for the purchase and sale of 40,000,000 common shares at a price of $0.20 per share and warrants to purchase up to 20,000,000 common shares with aggregate gross proceeds of C$8 million.

Aptose, headquartered in San Diego, California and Toronto, Ontario, Ontario, is a Canadian clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.

McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Soulière that included Shariff Farhiyah, Asma Boudoukha, Annie Poirier-Simard and Yassine Khadir (Business).